

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Orna Mor, et al.
U.S. Serial No. : 10/562,177
Filed : as S371 national stage of PCT
International Application No.
PCT/IL2004/000565
For : DIAGNOSIS AND TREATMENT OF FIBROSIS
RELATED PATHOLOGY

1185 Avenue of the Americas
New York, New York 10036
August 1, 2007

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**AMENDMENT IN RESPONSE TO FEBRUARY 9, 2007 NOTIFICATION TO
COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES
AND PETITION FOR FOUR-MONTH EXTENSION OF TIME**

This Amendment is submitted in response to the February 9, 2007 Notification to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures issued by the United States Patent and Trademark Office in connection with the above-identified application. The February 9, 2007 Notification, a copy of which is attached hereto as **Exhibit A**, provides two (2) months for filing a response. A response to the February 9, 2007 Notification was originally due April 9, 2007. Applicants hereby petition for a four-month extension of time under the provisions of 37 C.F.R. §1.136(a). The required fee for a four-month extension is SEVEN HUNDRED AND NINETY FIVE DOLLARS (\$795.00) for a small entity and a check including that amount is enclosed herewith. With a four-month extension of time, a response to the

Applicants: Orna Mor, et al.
U.S. Serial No.: 10/562,177
Filed: as S371 national stage of PCT/IL04/00565
Page 2

February 9, 2007 Notification is now due August 9, 2007.
Accordingly, this Amendment is being timely filed.

Please amend the subject application as follows:

Amendments to the Specification begin on page 3 of this paper.

A substitute **Sequence Listing** is referred to on page 6 of this paper and attached hereto as **Exhibit B**.

Remarks begin on page 7 of this paper.